Oncology

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

Australian biotech Amplia Therapeutics is bringing its promising pancreatic cancer trial to the US, a key step in developing a drug that targets the disease's defenses.

Bio-Techne promotes Steve Crouse to lead its high-growth Diagnostics and Spatial Biology unit, signaling a strategic focus on innovation after a key divestiture.

Radiation tech giant Mirion appoints three new executives, signaling a major strategic push into next-gen nuclear, advanced cancer care, and AI.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

Lantern's expanded cancer solution uses NCI-level expertise and community care to promise better outcomes and a significant return on investment for employers.

A new partnership with Uniphar will use managed access programs to provide the lymphoma therapy LYMPHIR to European patients with limited treatment options.

SOFIE Biosciences' FAPI-PRO trial begins, testing a novel radiotracer that could revolutionize the detection of one of the deadliest forms of cancer.

New 3D human tissue models show groundbreaking promise in predicting toxicity for advanced cancer therapies, heralding a major shift away from animal testing.

A newly identified molecule, HOXD13, both fuels melanoma growth and shields it from the immune system, paving the way for a novel combination therapy.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

Zelluna partners with Medpace for a first-in-human trial of its ZIMA-101 TCR-NK therapy, a new 'off-the-shelf' approach for hard-to-treat solid tumors.

A major new report reveals a deepening crisis in rural healthcare, as a $50 billion federal program clashes with devastating cuts, pushing a vital system to the brink.

New add-on tests from a single blood draw help oncologists avoid toxic chemo reactions and filter out false positives, aiming for safer, smarter cancer care.

Bolstered by a top regulatory expert and unique veterinary data, Vivos Inc. is set to file for human trials of its precision injectable cancer treatment.

With two high-profile board appointments, Stellaromics signals its ambition to dominate the 3D spatial omics market with its advanced Pyxa™ platform.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Israeli startup Protai is set to reveal promising preclinical data for its cancer drug, PRT-001, powered by its unique proteomics-aware AI platform.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.